E. Ohman J:Or Asset Management Ab Neurocrine Biosciences Inc Transaction History

E. Ohman J:Or Asset Management Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Apr 05, 2024	SELL	$92.03 - $107.81 $460,150 - $539,050	-5,000 Closed	0 $0
Q2 2022 Apr 05, 2024	BUY	$75.79 - $100.07 $250,107 - $330,231	3,300 Added 194.12%	5,000 $487 Million
Q1 2022 Apr 05, 2024	BUY	$72.45 - $94.81 $123,165 - $161,177	1,700 New	1,700 $159 Million
Q4 2021 Apr 05, 2024	SELL	$79.65 - $106.22 $310,635 - $414,258	-3,900 Closed	0 $0
Q2 2021 Apr 05, 2024	BUY	$89.43 - $102.27 $196,746 - $224,994	2,200 Added 129.41%	3,900 $380 Million

Q1 2021 Apr 05, 2024	BUY	$87.57 - $119.4 $148,869 - $202,980	1,700 New	1,700 $165 Million

628

94.4M

505K

343K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.3B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.